Skip to main content
Top
Published in: Magnetic Resonance Materials in Physics, Biology and Medicine 1/2003

01-02-2003 | Research Article

Reduced glutamate neurotransmission in patients with Alzheimer's disease–an in vivo 13C magnetic resonance spectroscopy study

Authors: Alexander P. Lin, Frederick Shic, Cathleen Enriquez, Brian D. Ross

Published in: Magnetic Resonance Materials in Physics, Biology and Medicine | Issue 1/2003

Login to get access

Abstract

Cognitive impairment in Alzheimer's disease (AD) is not fully explained. PET indicates reduced cerebral metabolic rate for glucose. Since glutamate neurotransmission (GNT) consumes more than 80% of the ATP generated from metabolism, a pilot study was carried out to determine the neuronal tricarboxylic acid cycle (TCA) based on the hypothesis that reduced GNT could contribute to cognitive impairment in AD.
Three AD patients with cognitive impairment (mini-mental state exam: 24 vs 30, P<0.05) and significant reduction in both N-acetyl aspartate (NAA)/Creatine (Cr) (P<0.009) and NAA/myo-inositol (mI) ratio (P<0.01), and three age-matched controls each received 0.014–0.016 g/kg/min 99%1–13C glucose IV. Quantitative 1H and proton-decoupled 13C MR brain spectra were acquired from combined posterior-parietal white matter and posterior-cingulate gray matter every 5 min for 140 min.
13C magnetic resonance spectroscopy (MRS) measures of glucose oxidation and neuronal TCA rate, including prolonged time to 13C enrichment of glutamate (Glu2) (P<0.004) and bicarbonate (HCO3) (P<0.03) as well as reduced relative enrichment of Glu2/Glu4 between 60 and 100 min (P<0.04), were significantly different in AD patients vs. controls. 13C measures of GNT, glutamine (Gln)2/Glu2 (P<0.02) and rates of glutamate enrichment (Glu2/glucose: 0.34 vs 0.86, P=ns and Glu4/glucose 0.26 vs 0.83, P=ns), were also reduced.
13C MRS measures of neuronal TCA cycle, glucose oxidation and GNT were significantly correlated with measures of neuronal integrity: NAA/Cr, [NAA] and mI/NAA as determined by 1H MRS (R 2=0.73–0.95; P<0.05–0.01), suggesting that impairment of GNT may be a contributing factor in the cognitive impairment characteristic of AD.
Literature
1.
go back to reference Alzheimer's Association: general statistics and demographics. http://www.alz.org/hc/overview/stats.htm Alzheimer's Association: general statistics and demographics. http://​www.​alz.​org/​hc/​overview/​stats.​htm
2.
go back to reference Alzheimer A, Stelzmann RA, Schnitzlein HN and Murtagh F (1995) An English translation of Alzheimer's 1907 paper, "Uber eine eigenartige Erkrankung der Hirnrinde". Clin Anat 8:429–431 Alzheimer A, Stelzmann RA, Schnitzlein HN and Murtagh F (1995) An English translation of Alzheimer's 1907 paper, "Uber eine eigenartige Erkrankung der Hirnrinde". Clin Anat 8:429–431
3.
go back to reference Morris RG (1991) The nature of memory impairment in Alzheimer-type dementia. In: Weinman J, Hunter J (eds) Memory: neurochemical and abnormal perspectives. Harwood, London, pp 56–59 Morris RG (1991) The nature of memory impairment in Alzheimer-type dementia. In: Weinman J, Hunter J (eds) Memory: neurochemical and abnormal perspectives. Harwood, London, pp 56–59
4.
go back to reference Knopman DS, DeKosky ST, Cummings JL, Chui H, Corey-Bloom J, Relkin N, Small GW, Miller B, Stevens JC (2001) Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology Neurology 56:1143–1153 Knopman DS, DeKosky ST, Cummings JL, Chui H, Corey-Bloom J, Relkin N, Small GW, Miller B, Stevens JC (2001) Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology Neurology 56:1143–1153
5.
go back to reference de Jager CA, Milwain E, Budge M (2002) Early detection of isolated memory deficits in the elderly: the need for more sensitive neuropsychological tests. Psychol Med 32:483–491 de Jager CA, Milwain E, Budge M (2002) Early detection of isolated memory deficits in the elderly: the need for more sensitive neuropsychological tests. Psychol Med 32:483–491
6.
go back to reference Cummings JL, Cole G (2002) Alzheimer disease. JAMA 287:2335–2338 Cummings JL, Cole G (2002) Alzheimer disease. JAMA 287:2335–2338
7.
go back to reference Braak H, Braak E (1991) Neuropathological staging of Alzheimer related changes. Acta Neuropathol 82:239–259 Braak H, Braak E (1991) Neuropathological staging of Alzheimer related changes. Acta Neuropathol 82:239–259
8.
go back to reference Gosche KM, Mortimer JA, Smith CD, Markesbery WR, Snowdon DA (2002) Hippocampal volume as an index of Alzheimer neuropathology: findings from the Nun Study. Neurology 58:1476–1482 Gosche KM, Mortimer JA, Smith CD, Markesbery WR, Snowdon DA (2002) Hippocampal volume as an index of Alzheimer neuropathology: findings from the Nun Study. Neurology 58:1476–1482
9.
go back to reference Jack Jr. CR, Petersen RC, Xu YC (1999) Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology 52:1397–1403 Jack Jr. CR, Petersen RC, Xu YC (1999) Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology 52:1397–1403
10.
go back to reference Holmes C (2002) Genotype and phenotype in Alzheimer's disease. Br J Psychiatry 180:131–134 Holmes C (2002) Genotype and phenotype in Alzheimer's disease. Br J Psychiatry 180:131–134
11.
go back to reference Isacson O, Seo H, Lin L, Albeck D, Granhom AC (2002) Alzheimer's disease and Down's syndrome: Roles of APP, trophic factors and ACh. Trends Neurosci 25:79–84 Isacson O, Seo H, Lin L, Albeck D, Granhom AC (2002) Alzheimer's disease and Down's syndrome: Roles of APP, trophic factors and ACh. Trends Neurosci 25:79–84
12.
go back to reference Schuff N, Amend D, Ezekiel F, Steinman SK, Tanabe J, Norman D, Jagust W, Kramer JH, Mastrianni JA, Fein G, Weiner MW (1997) Changes of hippocampal N-acetyl aspartate and volume in Alzheimer's disease. A proton MR spectroscopic imaging and MRI study. Neurology 49:1513–1521 Schuff N, Amend D, Ezekiel F, Steinman SK, Tanabe J, Norman D, Jagust W, Kramer JH, Mastrianni JA, Fein G, Weiner MW (1997) Changes of hippocampal N-acetyl aspartate and volume in Alzheimer's disease. A proton MR spectroscopic imaging and MRI study. Neurology 49:1513–1521
13.
go back to reference Moffett JR, Namboodiri MA, Neale JH(1993) Enhanced carbodiimide fixation for immunohistochemistry: application to the comparative distributions of N-acetylaspartylglutamate and N-acetylaspartate immunoreactivities in rat brain. J Histochem Cytochem 41:559–570 Moffett JR, Namboodiri MA, Neale JH(1993) Enhanced carbodiimide fixation for immunohistochemistry: application to the comparative distributions of N-acetylaspartylglutamate and N-acetylaspartate immunoreactivities in rat brain. J Histochem Cytochem 41:559–570
14.
go back to reference Moats RA, Ernst T, Shonk TK, Ross BD (1994) Abnormal cerebral metabolite concentrations in patients with probable Alzheimer disease. Magn Reson Med 32:110–115 Moats RA, Ernst T, Shonk TK, Ross BD (1994) Abnormal cerebral metabolite concentrations in patients with probable Alzheimer disease. Magn Reson Med 32:110–115
15.
go back to reference Kantarci K, Jack Jr. CR, Xu YC, Campeau NG, O'Brien PC, Smith GE, Ivnik RJ, Boeve BF, Kokmen E, Tangalos EG, Petersen RC (2000) Regional metabolic patterns in mild cognitive impairment and Alzheimer's disease: A 1H MRS study. Neurology 55:210–217 Kantarci K, Jack Jr. CR, Xu YC, Campeau NG, O'Brien PC, Smith GE, Ivnik RJ, Boeve BF, Kokmen E, Tangalos EG, Petersen RC (2000) Regional metabolic patterns in mild cognitive impairment and Alzheimer's disease: A 1H MRS study. Neurology 55:210–217
16.
go back to reference Huang W, Alexander GE, Chang L, Shetty HU, Krasuski JS, Rapoport SI, Schapiro MB (2001) Brain metabolite concentration and dementia severity in Alzheimer's disease: a (1)H MRS study. Neurology 57:626–632 Huang W, Alexander GE, Chang L, Shetty HU, Krasuski JS, Rapoport SI, Schapiro MB (2001) Brain metabolite concentration and dementia severity in Alzheimer's disease: a (1)H MRS study. Neurology 57:626–632
17.
go back to reference Shonk TK, Moats RA, Gifford P, Michaelis T, Mandigo JC, Izumi J, Ross BD (1995) Probable Alzheimer disease: diagnosis with proton MR spectroscopy. Radiology 195:65–72 Shonk TK, Moats RA, Gifford P, Michaelis T, Mandigo JC, Izumi J, Ross BD (1995) Probable Alzheimer disease: diagnosis with proton MR spectroscopy. Radiology 195:65–72
18.
go back to reference Lin A, Sheih D, Shic F, Chien TY, Ross BD (2002) Validation of MRS in early diagnosis of Alzheimer's disease. J Geriatric Psychiatry Neurol p.176 Lin A, Sheih D, Shic F, Chien TY, Ross BD (2002) Validation of MRS in early diagnosis of Alzheimer's disease. J Geriatric Psychiatry Neurol p.176
19.
go back to reference Ross BD, Bluml S, Cowan R, Danielsen E, Farrow N, Gruetter R (1997) In vivo magnetic resonance spectroscopy of human brain: The biophysical basis of dementia. Biophys Chem 68:161–172 Ross BD, Bluml S, Cowan R, Danielsen E, Farrow N, Gruetter R (1997) In vivo magnetic resonance spectroscopy of human brain: The biophysical basis of dementia. Biophys Chem 68:161–172
20.
go back to reference Hattori N, Abe K, Sakoda S, Sawada T 2002 Proton MR spectroscopic study at 3 Tesla on glutamate/glutamine in Alzheimer's disease. Neuroreport 13:183–186 Hattori N, Abe K, Sakoda S, Sawada T 2002 Proton MR spectroscopic study at 3 Tesla on glutamate/glutamine in Alzheimer's disease. Neuroreport 13:183–186
21.
go back to reference Antuono PG, Jones JL, Wang Y, Li SJ (2001) Decreased glutamate + glutamine in Alzheimer's disease detected in vivo with (1)H-MRS at 0.5 T. Neurology 56:737–742 Antuono PG, Jones JL, Wang Y, Li SJ (2001) Decreased glutamate + glutamine in Alzheimer's disease detected in vivo with (1)H-MRS at 0.5 T. Neurology 56:737–742
22.
go back to reference Reinikainen KJ, Paljarvi L, Huuskonen M, Soininen H, Laakso M and Riekkinen PJ (1988) A post-mortem study of noradrenergic, serotonergic and GABAergic neurons in Alzheimer's disease. J Neurol Sci 84:101–116 Reinikainen KJ, Paljarvi L, Huuskonen M, Soininen H, Laakso M and Riekkinen PJ (1988) A post-mortem study of noradrenergic, serotonergic and GABAergic neurons in Alzheimer's disease. J Neurol Sci 84:101–116
23.
go back to reference Beal MF (1995) Aging, energy, and oxidative stress in neurodegenerative diseases. Ann Neurol 38:357–366 Beal MF (1995) Aging, energy, and oxidative stress in neurodegenerative diseases. Ann Neurol 38:357–366
24.
go back to reference Smith CD, Pettigrew LC, Avison MJ, Kirsch JE, Tinkhtman AJ, Schmitt FA, Wermeling DP, Wekstein DR, Markesberry WR (1995) Frontal lobe phosphorus metabolism and neuropsychological function in aging and in Alzheimer's disease. Ann Neurol 38:194–201 Smith CD, Pettigrew LC, Avison MJ, Kirsch JE, Tinkhtman AJ, Schmitt FA, Wermeling DP, Wekstein DR, Markesberry WR (1995) Frontal lobe phosphorus metabolism and neuropsychological function in aging and in Alzheimer's disease. Ann Neurol 38:194–201
25.
go back to reference Bluml S, Danielsen ER, Ross BD (1996) Proton decoupled 31P MRS in Alzheimer disease. Proceedings, 4th International Society of Magnetic Resonance in Medicine, vol 1. New York, p. 304 Bluml S, Danielsen ER, Ross BD (1996) Proton decoupled 31P MRS in Alzheimer disease. Proceedings, 4th International Society of Magnetic Resonance in Medicine, vol 1. New York, p. 304
26.
go back to reference Ross BD, Bluml S, Cowan R, Danielsen E, Farrow N, Gruetter R, Tan J (1998) In vivo MRS spectroscopy of human dementia. Neuroimaging Clinics of North America. 8:1–14 Ross BD, Bluml S, Cowan R, Danielsen E, Farrow N, Gruetter R, Tan J (1998) In vivo MRS spectroscopy of human dementia. Neuroimaging Clinics of North America. 8:1–14
27.
go back to reference Silverman DH, Small GW, Chang CY, Lu CS, Kung De Aburto MA, Chen W, Czernin J, Rapoport SI, Pietrini P, Alexander GE, Schapiro MB, Jagust WJ, Hoffman JM, Welsh-Bohmer KA, Alavi A, Clark CM, Salmon E, de Leon MJ, Mielke R, Cummings JL, Kowell AP, Gambhir SS, Hoh CK, Phelps ME (2001) Positron emission tomography in evaluation of dementia: regional brain metabolism and long-term outcome. JAMA 286:2120–2127 Silverman DH, Small GW, Chang CY, Lu CS, Kung De Aburto MA, Chen W, Czernin J, Rapoport SI, Pietrini P, Alexander GE, Schapiro MB, Jagust WJ, Hoffman JM, Welsh-Bohmer KA, Alavi A, Clark CM, Salmon E, de Leon MJ, Mielke R, Cummings JL, Kowell AP, Gambhir SS, Hoh CK, Phelps ME (2001) Positron emission tomography in evaluation of dementia: regional brain metabolism and long-term outcome. JAMA 286:2120–2127
28.
go back to reference Desgranges B, Baron JC, Lalevee C, Giffard B, Viader F, de La Sayette V, Eustache F (2002) The neural substrates of episodic memory impairment in Alzheimer's disease as revealed by FDG-PET: relationship to degree of deterioration. Brain 125:1116–1124 Desgranges B, Baron JC, Lalevee C, Giffard B, Viader F, de La Sayette V, Eustache F (2002) The neural substrates of episodic memory impairment in Alzheimer's disease as revealed by FDG-PET: relationship to degree of deterioration. Brain 125:1116–1124
29.
go back to reference Schulman RJ (2001) Functional imaging studies: Linking mind and basic neuroscience. Am J Psychiatry 158:11–20 Schulman RJ (2001) Functional imaging studies: Linking mind and basic neuroscience. Am J Psychiatry 158:11–20
30.
go back to reference Magistretti PJ, Pellerin L, Rothman DL, Shulman RG (1999) Energy on demand. Science 283:496–497 Magistretti PJ, Pellerin L, Rothman DL, Shulman RG (1999) Energy on demand. Science 283:496–497
31.
go back to reference Attwell D, Laughlin SB (2001) An energy budget for signaling in the grey matter of the brain. J Cereb Blood Flow Metab 21:1135–1145 Attwell D, Laughlin SB (2001) An energy budget for signaling in the grey matter of the brain. J Cereb Blood Flow Metab 21:1135–1145
32.
go back to reference Beckmann N, Seelig J, Wick H (1990) Analysis of glycogen storage disease by in vivo 13C NMR: comparison of normal volunteers with a patient. Magn Reson Med 16:150–160 Beckmann N, Seelig J, Wick H (1990) Analysis of glycogen storage disease by in vivo 13C NMR: comparison of normal volunteers with a patient. Magn Reson Med 16:150–160
33.
go back to reference Mason GF, Rothman DL, Behar KL, Shulman RG (1992) NMR determination of the TCA cycle rate and α-ketoglutarate/glutamate exchange rate in rat brain. J Cereb Blood Flow Metab 12:434–447 Mason GF, Rothman DL, Behar KL, Shulman RG (1992) NMR determination of the TCA cycle rate and α-ketoglutarate/glutamate exchange rate in rat brain. J Cereb Blood Flow Metab 12:434–447
34.
go back to reference Gruetter R, Seaquist ER, Kim S, Ugurbil K(1998) Localized in vivo 13C-NMR of glutamate metabolism in the human brain: Initial results at 4 Tesla. Dev Neurosci 20:380–388 Gruetter R, Seaquist ER, Kim S, Ugurbil K(1998) Localized in vivo 13C-NMR of glutamate metabolism in the human brain: Initial results at 4 Tesla. Dev Neurosci 20:380–388
35.
go back to reference Moreno A, Bluml S, Hwang J-H, Ross BD (2001) Alternative 1–13C glucose infusion protocols for clinical 13C MRS examinations of the brain. Magn Reson Med 46:36–48 Moreno A, Bluml S, Hwang J-H, Ross BD (2001) Alternative 1–13C glucose infusion protocols for clinical 13C MRS examinations of the brain. Magn Reson Med 46:36–48
36.
go back to reference Kreis R, Ernst T, Ross BD (1993) Absolute quantitation of water and metabolites in the human brain. Part II. Metabolite concentrations. J Magn Reson 102:9–19 Kreis R, Ernst T, Ross BD (1993) Absolute quantitation of water and metabolites in the human brain. Part II. Metabolite concentrations. J Magn Reson 102:9–19
37.
go back to reference Ernst T, Kreis R, Ross BD (1993) Absolute quantitation of water and metabolites in the human brain. I. Compartments and water. J Magn Reson 102:1–8 Ernst T, Kreis R, Ross BD (1993) Absolute quantitation of water and metabolites in the human brain. I. Compartments and water. J Magn Reson 102:1–8
38.
go back to reference Bluml S, Hwang J-H, Moreno A, Ross BD (2000) Novel peak assignments of in vivo 13C MRS in human brain at 1.5 T. J Magn Reson 143:292–298 Bluml S, Hwang J-H, Moreno A, Ross BD (2000) Novel peak assignments of in vivo 13C MRS in human brain at 1.5 T. J Magn Reson 143:292–298
39.
go back to reference Adriany G, Gruetter R (1997) A half-volume coil for efficient proton decoupling in humans at 4 Tesla. J Magn Reson 125:178–184 Adriany G, Gruetter R (1997) A half-volume coil for efficient proton decoupling in humans at 4 Tesla. J Magn Reson 125:178–184
40.
go back to reference Bluml S (1999) In vivo quantitation of cerebral metabolites concentration using natural abundance 13C MRS at 1.5 T. J Magn Reson 136:219–225 Bluml S (1999) In vivo quantitation of cerebral metabolites concentration using natural abundance 13C MRS at 1.5 T. J Magn Reson 136:219–225
41.
go back to reference Shaka AJ, Keeler J, Frenkiel T and Freeman R. An improved sequence for broadband decoupling: WALTZ-16. J Magn Reson 198352:335–338 Shaka AJ, Keeler J, Frenkiel T and Freeman R. An improved sequence for broadband decoupling: WALTZ-16. J Magn Reson 198352:335–338
42.
go back to reference Shaka AJ, Keeler J and Freeman R (1983) Evaluation of a new broadband decoupling sequence: WALTZ-16. J Magn Reson 53:313–340 Shaka AJ, Keeler J and Freeman R (1983) Evaluation of a new broadband decoupling sequence: WALTZ-16. J Magn Reson 53:313–340
43.
go back to reference Gruetter R, Adriany G, Merkle H and Anderson PM (1996) Broadband decoupled 1H-localized 13C MRS of the human brain at 4 Tesla. Magn Reson Med 36:659 Gruetter R, Adriany G, Merkle H and Anderson PM (1996) Broadband decoupled 1H-localized 13C MRS of the human brain at 4 Tesla. Magn Reson Med 36:659
44.
go back to reference Bluml S, Moreno-Torres A, Ross BD (2001) [1–13C] glucose MRS in chronic hepatic encephalopathy in man. Magn Reson Med 45:981–993 Bluml S, Moreno-Torres A, Ross BD (2001) [1–13C] glucose MRS in chronic hepatic encephalopathy in man. Magn Reson Med 45:981–993
45.
go back to reference Shic F, Lin A, Ross BD (2002) Automated methods for analysis of large quantitites of13C MRS data in clinical studies. J Magn Reson (in press) Shic F, Lin A, Ross BD (2002) Automated methods for analysis of large quantitites of13C MRS data in clinical studies. J Magn Reson (in press)
46.
go back to reference Mason GF, Behar KL, Rothman DL, Shulman RG (1992) NMR determination of intracerebral glucose concentration and transport kinetics in rat brain. J Cereb Blood Flow Metab 12:448–455 Mason GF, Behar KL, Rothman DL, Shulman RG (1992) NMR determination of intracerebral glucose concentration and transport kinetics in rat brain. J Cereb Blood Flow Metab 12:448–455
47.
go back to reference Mason GF, Gruetter R, Rothman DL, Behar KL, Shulman RG, Novotny EJ (1995) Simultaneous determination of the rates of the TCA cycle, glucose utilization, a-ketoglutarate/glutamate exchange, and glutamine synthesis in human brain by NMR. J Cereb Blood Flow Metab 15:12–25 Mason GF, Gruetter R, Rothman DL, Behar KL, Shulman RG, Novotny EJ (1995) Simultaneous determination of the rates of the TCA cycle, glucose utilization, a-ketoglutarate/glutamate exchange, and glutamine synthesis in human brain by NMR. J Cereb Blood Flow Metab 15:12–25
48.
go back to reference Bluml S, Moreno A, Hwang J-H, Ross BD (2001) 1–13C glucose magnetic resonance spectroscopy of pediatric and adult brain disorders. NMR Biomed 14:19–32 Bluml S, Moreno A, Hwang J-H, Ross BD (2001) 1–13C glucose magnetic resonance spectroscopy of pediatric and adult brain disorders. NMR Biomed 14:19–32
49.
go back to reference Bluml S, Moreno-Torres A, Shic F, Nguy C-H, Ross BD 2002 Tricarboxylic acid cycle of glia in the in vivo human brain. NMR Biomed 15:1–5 Bluml S, Moreno-Torres A, Shic F, Nguy C-H, Ross BD 2002 Tricarboxylic acid cycle of glia in the in vivo human brain. NMR Biomed 15:1–5
50.
go back to reference Lebon V, Peterson K, Cline GW, et. al (2002) Astroglial contribution to brain energy metabolism in humans revealed by13C nuclear magnetic resonance spectroscopy: elucidation of the dominant pathway for neurotransmitter glutamate repletion and measurement of astrocytic oxidative metabolism. J Neurosci 22:1523–1531 Lebon V, Peterson K, Cline GW, et. al (2002) Astroglial contribution to brain energy metabolism in humans revealed by13C nuclear magnetic resonance spectroscopy: elucidation of the dominant pathway for neurotransmitter glutamate repletion and measurement of astrocytic oxidative metabolism. J Neurosci 22:1523–1531
51.
go back to reference Lentner C (1982) In: Lentner C (ed) Introduction to statistics. Ciba-Geigy, Basel, p 49 Lentner C (1982) In: Lentner C (ed) Introduction to statistics. Ciba-Geigy, Basel, p 49
52.
go back to reference Moreno A, Ross BD, Bluml S (2001) Direct determination of the N-acetyl-L-aspartate synthesis rate in the human 13C MRS and [1–13C] glucose infusion. J Neurochem 77:347–350 Moreno A, Ross BD, Bluml S (2001) Direct determination of the N-acetyl-L-aspartate synthesis rate in the human 13C MRS and [1–13C] glucose infusion. J Neurochem 77:347–350
53.
go back to reference Sibson NR, Dhankhar A, Mason GF, Rothman DL, Behar KL, Shulman RG (1998) Stoichiometric coupling between brain glucose metabolism and glutamatergic neuronal activity. Proc Natl Acad Sci USA 95:316–321 Sibson NR, Dhankhar A, Mason GF, Rothman DL, Behar KL, Shulman RG (1998) Stoichiometric coupling between brain glucose metabolism and glutamatergic neuronal activity. Proc Natl Acad Sci USA 95:316–321
54.
go back to reference Gruetter R, Seaquist ER, Ugurbil K (2001) A mathematical model of compartmentalized neurotransmitter metabolism in the human brain. Am J Physiol Endocrinol Metab 281:E100-E112 Gruetter R, Seaquist ER, Ugurbil K (2001) A mathematical model of compartmentalized neurotransmitter metabolism in the human brain. Am J Physiol Endocrinol Metab 281:E100-E112
55.
go back to reference Lewandowski ED, Hulbert C (1991) Dynamic changes in 13C NMR spectra of intact hearts under conditions of varied metabolite enrichment. Magn Reson Med 19:186–190 Lewandowski ED, Hulbert C (1991) Dynamic changes in 13C NMR spectra of intact hearts under conditions of varied metabolite enrichment. Magn Reson Med 19:186–190
56.
go back to reference Janus C, Westaway D (2001) Transgenic mouse models of Alzheimer's disease. Physiol Behav 73:873–886 Janus C, Westaway D (2001) Transgenic mouse models of Alzheimer's disease. Physiol Behav 73:873–886
57.
go back to reference Anger WK (1991) Animal test systems to study behavioral dysfunctions of neurodegenerative disorders. Neurotoxicology 12:403–413 Anger WK (1991) Animal test systems to study behavioral dysfunctions of neurodegenerative disorders. Neurotoxicology 12:403–413
58.
go back to reference Robinson SR (2001) Changes in the cellular distribution of glutamine synthetase in Alzheimer's disease. J Neurosci Res 66:972–980 Robinson SR (2001) Changes in the cellular distribution of glutamine synthetase in Alzheimer's disease. J Neurosci Res 66:972–980
59.
go back to reference Baslow M (2000) Functions of N-acetyl-l-aspartate and N-acetyl-l-aspartylglutamate in the vertebrate brain: role in glial cell-specific signaling. J Neurochem 75:453–459 Baslow M (2000) Functions of N-acetyl-l-aspartate and N-acetyl-l-aspartylglutamate in the vertebrate brain: role in glial cell-specific signaling. J Neurochem 75:453–459
60.
go back to reference Kanamori K, Ross BD (2001) The first in vivo observation of 13C-15 N coupling in mammalian brain. J Magn Reson 153:193–202 Kanamori K, Ross BD (2001) The first in vivo observation of 13C-15 N coupling in mammalian brain. J Magn Reson 153:193–202
Metadata
Title
Reduced glutamate neurotransmission in patients with Alzheimer's disease–an in vivo 13C magnetic resonance spectroscopy study
Authors
Alexander P. Lin
Frederick Shic
Cathleen Enriquez
Brian D. Ross
Publication date
01-02-2003
Publisher
Springer-Verlag
Published in
Magnetic Resonance Materials in Physics, Biology and Medicine / Issue 1/2003
Print ISSN: 0968-5243
Electronic ISSN: 1352-8661
DOI
https://doi.org/10.1007/s10334-003-0004-x

Other articles of this Issue 1/2003

Magnetic Resonance Materials in Physics, Biology and Medicine 1/2003 Go to the issue